MedTrace Logo

Identification of Epigenetic Biomarkers for Early Detection of Rheumatic Disease

NCT02742337 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2016-04-19

No results posted yet for this study

Summary

• Given the cost and risk associated with biologic disease modifying anti-rheumatic drugs (bDMARDs), selection of the optimal medication is imperative. Current attempts to identify genetic factors that predict bDMARD response and effectiveness in rheumatoid arthritis patients have been inconclusive. Furthermore the presence of epigenetic signatures in rheumatoid arthritis patients has not been established. This protocol is the first step to identifying the practicality and feasibility of epigenetic testing to aid in diagnosis and/or medication selection in rheumatoid arthritis patients. Subsequent research into such epigenetic changes may be indicative of bDMARD response and/or safety. If such epigenetic signatures (EGS) exist the business need for such tests will thus be supported.

Conditions

  • Arthritis, Rheumatoid

Sponsors & Collaborators

  • Epigenesys LLC

    collaborator UNKNOWN

  • Arthritis Northwest PLLC

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02742337 on ClinicalTrials.gov